(WKL) Wolters Kluwer - Overview
Stock: Health Software, Tax Solutions, Compliance Tools, Legal Research, ESG Platform
Dividends
| Dividend Yield | 1.78% |
| Yield on Cost 5y | 3.85% |
| Yield CAGR 5y | 14.17% |
| Payout Consistency | 99.1% |
| Payout Ratio | 90.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 52.8% |
| Relative Tail Risk | -5.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -3.10 |
| Alpha | -67.26 |
| Character TTM | |
|---|---|
| Beta | 0.120 |
| Beta Downside | 0.027 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.88% |
| CAGR/Max DD | -0.22 |
Description: WKL Wolters Kluwer December 17, 2025
Wolters Kluwer N.V. (AS: WKL) is a global provider of professional information, software and services, operating across Health; Tax & Accounting; Financial & Corporate Compliance; Legal & Regulatory; and Corporate Performance & ESG segments. Its offerings span clinical decision-support tools for hospitals and digital-health firms, compliance platforms for tax, audit and legal professionals, and enterprise software that helps corporations meet financial, sustainability and safety reporting requirements. The company, founded in 1836, is headquartered in Alphen aan den Rijn, the Netherlands, and serves customers in Europe, North America, APAC, Africa and beyond.
Key recent metrics: FY 2023 revenue reached roughly €6.2 billion, up about 5 % YoY, with an operating margin near 21 %; the Tax & Accounting segment contributed ~35 % of total revenue, while the Health segment saw double-digit growth driven by accelerated adoption of tele-health and AI-enabled diagnostics. Macro-level drivers include rising regulatory spending worldwide, heightened ESG reporting mandates, and continued digital transformation in both healthcare and financial services, which together underpin demand for Wolters Kluwer’s compliance and performance-management solutions.
For a deeper, data-rich breakdown of these trends, you may find the ValueRay platform a useful resource for further research.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 2.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.29 > 0.02 and ΔFCF/TA 12.26 > 1.0 |
| NWC/Revenue: -8.94% < 20% (prev -15.51%; Δ 6.57% < -1%) |
| CFO/TA 0.33 > 3% & CFO 3.19b > Net Income 2.16b |
| Net Debt (4.29b) to EBITDA (3.84b): 1.12 < 3 |
| Current Ratio: 0.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (234.0m) vs 12m ago -5.65% < -2% |
| Gross Margin: 66.49% > 18% (prev 0.71%; Δ 6578 % > 0.5%) |
| Asset Turnover: 125.7% > 50% (prev 61.38%; Δ 64.31% > 0%) |
| Interest Coverage Ratio: 32.49 > 6 (EBITDA TTM 3.84b / Interest Expense TTM 89.0m) |
Altman Z'' 1.90
| A: -0.11 (Total Current Assets 2.61b - Total Current Liabilities 3.67b) / Total Assets 9.73b |
| B: 0.14 (Retained Earnings 1.36b / Total Assets 9.73b) |
| C: 0.31 (EBIT TTM 2.89b / Avg Total Assets 9.41b) |
| D: 0.09 (Book Value of Equity 800.0m / Total Liabilities 8.85b) |
| Altman-Z'' Score: 1.90 = BBB |
Beneish M -2.64
| DSRI: 0.52 (Receivables 1.60b/1.46b, Revenue 11.83b/5.58b) |
| GMI: 1.07 (GM 66.49% / 71.01%) |
| AQI: 1.05 (AQ_t 0.71 / AQ_t-1 0.67) |
| SGI: 2.12 (Revenue 11.83b / 5.58b) |
| TATA: -0.11 (NI 2.16b - CFO 3.19b) / TA 9.73b) |
| Beneish M-Score: -2.64 (Cap -4..+1) = A |
What is the price of WKL shares?
Over the past week, the price has changed by -14.17%, over one month by -25.37%, over three months by -32.57% and over the past year by -60.97%.
Is WKL a buy, sell or hold?
What are the forecasts/targets for the WKL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 139.7 | 106.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 50.6 | -25.3% |
WKL Fundamental Data Overview February 03, 2026
P/E Trailing = 16.5714
P/E Forward = 14.1443
P/S = 2.9319
P/B = 20.1594
P/EG = 1.5377
Revenue TTM = 11.83b EUR
EBIT TTM = 2.89b EUR
EBITDA TTM = 3.84b EUR
Long Term Debt = 4.45b EUR (from longTermDebt, last quarter)
Short Term Debt = 600.0m EUR (from shortTermDebt, last quarter)
Debt = 5.23b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.29b EUR (from netDebt column, last quarter)
Enterprise Value = 22.11b EUR (17.82b + Debt 5.23b - CCE 942.0m)
Interest Coverage Ratio = 32.49 (Ebit TTM 2.89b / Interest Expense TTM 89.0m)
EV/FCF = 7.75x (Enterprise Value 22.11b / FCF TTM 2.85b)
FCF Yield = 12.91% (FCF TTM 2.85b / Enterprise Value 22.11b)
FCF Margin = 24.13% (FCF TTM 2.85b / Revenue TTM 11.83b)
Net Margin = 18.26% (Net Income TTM 2.16b / Revenue TTM 11.83b)
Gross Margin = 66.49% ((Revenue TTM 11.83b - Cost of Revenue TTM 3.96b) / Revenue TTM)
Gross Margin QoQ = 65.20% (prev 64.33%)
Tobins Q-Ratio = 2.27 (Enterprise Value 22.11b / Total Assets 9.73b)
Interest Expense / Debt = 0.73% (Interest Expense 38.0m / Debt 5.23b)
Taxrate = 23.93% (174.0m / 727.0m)
NOPAT = 2.20b (EBIT 2.89b * (1 - 23.93%))
Current Ratio = 0.71 (Total Current Assets 2.61b / Total Current Liabilities 3.67b)
Debt / Equity = 5.90 (Debt 5.23b / totalStockholderEquity, last quarter 887.0m)
Debt / EBITDA = 1.12 (Net Debt 4.29b / EBITDA 3.84b)
Debt / FCF = 1.50 (Net Debt 4.29b / FCF TTM 2.85b)
Total Stockholder Equity = 1.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 22.96% (Net Income 2.16b / Total Assets 9.73b)
RoE = 151.1% (Net Income TTM 2.16b / Total Stockholder Equity 1.43b)
RoCE = 49.15% (EBIT 2.89b / Capital Employed (Equity 1.43b + L.T.Debt 4.45b))
RoIC = 40.92% (NOPAT 2.20b / Invested Capital 5.38b)
WACC = 5.04% (E(17.82b)/V(23.05b) * Re(6.36%) + D(5.23b)/V(23.05b) * Rd(0.73%) * (1-Tc(0.24)))
Discount Rate = 6.36% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.16%
[DCF Debug] Terminal Value 87.20% ; FCFF base≈2.33b ; Y1≈2.56b ; Y5≈3.26b
Fair Price DCF = 407.3 (EV 96.23b - Net Debt 4.29b = Equity 91.94b / Shares 225.7m; r=5.90% [WACC]; 5y FCF grow 11.08% → 2.90% )
EPS Correlation: -10.55 | EPS CAGR: -60.51% | SUE: 0.0 | # QB: 0
Revenue Correlation: 68.58 | Revenue CAGR: 10.68% | SUE: -0.02 | # QB: 0
EPS next Year (2026-12-31): EPS=5.76 | Chg30d=+0.003 | Revisions Net=-3 | Growth EPS=+9.2% | Growth Revenue=+3.3%